BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024

  United Therapeutics Corporation, announced that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024.

  February 14, 2024

   · 

  2 min read
• Freudenberg Medical establishes second production facility in Costa Rica

  Freudenberg Medical, a global contract design and manufacturing partner to the medical device and biopharma industry with facilities in key industry hubs across the Americas, Europe and Asia, announced it is to establish a second manufacturing site in Costa Rica.

  February 14, 2024

   · 

  4 min read
• Biotech Beach

  BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement

  BIOLASE, Inc. announced that it received notice from the Staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550.

  February 14, 2024

   · 

  3 min read
• enGene Announces Leadership Succession Plan - February 14, 2024

  enGene Holdings Inc. announced that due to personal family and health reasons, Jason Hanson intends to resign from his role as Chief Executive Officer and a member of the Board of Directors upon the appointment of a successor CEO.

  February 14, 2024

   · 

  5 min read
• CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU

  Galderma announced that the U.S. Food and Drug Administration has accepted its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis and for adolescents and adults with moderate to severe atopic dermatitis.

  February 14, 2024

   · 

  12 min read
• enGene Announces Oversubscribed $200 Million Private Placement Financing

  enGene Holdings Inc. announced that it has agreed to sell 20 million of its common shares at a price per share of $10.00, representing a 31% premium over the closing price on February 13, 2024.

  February 14, 2024

   · 

  5 min read
• Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

  Opthea Limited announced that it has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept -C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration.

  February 14, 2024

   · 

  9 min read
• BioMidwest

  Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

  Cogent Biosciences, Inc. announced it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $225 million to the Company, before deducting placement agent fees and offering expenses.

  February 14, 2024

   · 

  7 min read
• Drug Development

  Flamingo Therapeutics Announces First Patient Dosed in Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)

  Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent/metastatic head and neck squamous cell carcinoma.

  February 14, 2024

   · 

  3 min read
• Business

  PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

  PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, provided a corporate update and reported financial results for the three months and full year ended December 31, 2023.

  February 14, 2024

   · 

  10 min read